GR-1 and RC-14 are two named probiotic strains studied for vaginal flora balance, and trial results on them are mixed, not settled.
A bottle labeled only Lactobacillus rhamnosus can sit beside one labeled GR-1 and cost half as much. They are not the same thing. Two proprietary strains — Lactobacillus GR-1 and RC-14 — carry their own published trial record, and it is more uneven than most supplement labels let on. Here is what the names certify and where the evidence runs out.
Lactobacillus GR-1 And RC-14: What The Strain Names Decide
GR-1 and RC-14 are bacterial strains with published identifiers, not two species, and those identifiers are the only dependable proof that a product holds the studied organisms. GR-1 is registered as ATCC 55826 and RC-14 as ATCC 55845.
Both were first classified under older genus names. GR-1 started as Lactobacillus rhamnosus and is now Lacticaseibacillus rhamnosus. RC-14 started as Lactobacillus fermentum and is now Limosilactobacillus reuteri. A label printing the old names is not out of date. A label printing only the species name tells you almost nothing.
That distinction has practical weight. Dozens of Lactobacillus rhamnosus and Limosilactobacillus reuteri products exist with completely different trial histories, and a strain designation is the difference between a claim and a citation.
Do The Clinical Trials Actually Support The Benefits?
The trials support a modest, strain-specific shift in vaginal flora for some women.
A 2003 randomized trial in FEMS Immunology and Medical Microbiology enrolled 64 healthy women who took GR-1 plus RC-14 orally for 60 days. Flora shifted from asymptomatic BV-type patterns to lactobacilli-dominated patterns in 37% of the treated group against 13% on placebo, and vaginal lactobacilli rose while yeast and coliform counts fell. No adverse effects were reported.
Among 11 women with BV, 7 reached normal or intermediate Nugent scores within a month.
Later work is less flattering. A 2021 trial of 126 women with BV added oral GR-1 and RC-14 to metronidazole for 30 days and found no meaningful gain in cure rates at 30 or 90 days over metronidazole alone. The strains were rarely recovered from vaginal or fecal samples afterward.
Vaginal delivery has been tested too. A 2014 crossover study gave 14 postmenopausal women 2.5 billion CFU of each strain vaginally for three days; Lactobacillus abundance rose, Nugent scores did not improve. For recurrent yeast infections the evidence is thin, and a European scientific review found no established cause-and-effect relationship for the combination’s claimed defense against vaginal pathogens.
| Study | Design | Main Finding |
|---|---|---|
| 2001 dosing study | 42 healthy women, oral, 28 days | Healthy flora in up to 90%; 7 of 11 BV cases improved |
| 2003 randomized trial | 64 healthy women, oral, 60 days | Normal flora restored in 37% vs 13% on placebo |
| 2014 crossover study | 14 postmenopausal women, vaginal, 3 days | Lactobacillus abundance rose; Nugent scores unchanged |
| 2021 BV trial | 126 women with BV, oral, 30 days, added to metronidazole | No gain in cure rates at 30 or 90 days |
| 2024 review | Multiple regimens, 1 to 25 billion CFU/mL, 30 days to 12 weeks | Mixed outcomes across formulations and doses |
| Candidiasis reviews | Small, methodologically weak trials | No reliable prevention or treatment shown |
Dosing In The Studies Vs. Dosing On The Label
Study doses and label doses are not the same thing, and no single amount has been validated across every use. A 2024 review covers regimens from about 1 billion to 25 billion CFU per milliliter over 30 days to 12 weeks, with mixed outcomes. Higher CFU is not automatically better, and vaginal delivery is not automatically superior to oral.
- No verified current US retail price, package size, or lot-specific potency data exists for any branded product. Check the authorized listing and the printed Supplement Facts panel before buying.
- Safety looked unremarkable in the trials that reported it, and reviews found no major concerns — but the strains are rarely detected long after dosing stops, so don’t count on lasting colonization.
- Pregnancy evidence is formulation-specific. A 2024 review covers 1 billion and 2.5 billion CFU/mL regimens, including one large study with no adverse pregnancy outcomes, which does not make every product or dose appropriate while pregnant.
Supplements are not a substitute for diagnosis. Odor, abnormal discharge, pelvic pain, fever, bleeding, pregnancy-related symptoms, or an infection that keeps returning all call for medical evaluation, and prescribed antibiotics or antifungals should never be delayed or swapped.
Sorting bottles by strain first beats sorting by price, and a tested GR-1 and RC-14 probiotic roundup does that filtering for you.
Common Questions
Are GR-1 And RC-14 The Same As Lactobacillus rhamnosus GG?
No. GG is a separate strain with its own trial history, mostly studied for gut and immune outcomes. GR-1 and RC-14 were tested together for vaginal flora, and the 2001 comparison found the pair outperformed GG on that measure. A product using GG is not a stand-in for one carrying the GR-1 and RC-14 designations.
Can These Strains Cure Bacterial Vaginosis?
No. Nothing in the published record supports a cure claim. The 2021 trial found the strains added nothing to metronidazole at 30 or 90 days, and the earlier positive results involved flora shifts rather than confirmed cures. BV needs diagnosis and standard treatment; a probiotic is at most something to discuss with a clinician alongside it.
How Long Before You Notice Anything?
Weeks, not days. Positive flora changes in the human trials appeared over 28 to 60 days of daily use, and the trial with 90-day follow-up found no added benefit. If a symptom is getting worse rather than holding steady, waiting out a trial period is the wrong move.
Sources
- FEMS Immunology and Medical Microbiology (Oxford Academic). “Oral administration of Lactobacillus GR-1 and RC-14 (2003 randomized trial)” Supports the 37% vs 13% flora restoration result and the no-adverse-effects finding.
- FEMS Immunology and Medical Microbiology (Oxford Academic). “Dosing study comparing GR-1 and RC-14 with Lactobacillus rhamnosus GG (2001)” Supports the up-to-90% healthy flora figure and the 100 million organism daily threshold.
- National Institutes of Health, PubMed Central. “Oral GR-1 and RC-14 as an adjunct to metronidazole in bacterial vaginosis (2021 trial)” Supports the null cure-rate result at 30 and 90 days and the rare post-dose detection finding.